[HTML][HTML] Comparative analysis of first-line treatment regimens for advanced EGFR-mutant non-small cell lung cancer patients with stable brain metastases
L Dai, CY Luo, GX Hu, G Chen, CX Wu… - Annals of Palliative …, 2020 - apm.amegroups.org
Background: To compare the survival outcomes of first-line treatment regimens for advanced
epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) …
epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) …
Chemotherapy and EGFR tyrosine kinase inhibitors for treatment of brain metastases from non-small-cell lung cancer: survival analysis in 210 patients
Y Fan, Z Huang, L Fang, L Miu, N Lin… - OncoTargets and …, 2013 - Taylor & Francis
Background Chemotherapy and epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors are controversial in the treatment of patients with brain metastases from non-small …
inhibitors are controversial in the treatment of patients with brain metastases from non-small …
EGFR-TKI therapy for patients with brain metastases from non-small-cell lung cancer: a pooled analysis of published data
Y Fan, X Xu, C Xie - OncoTargets and therapy, 2014 - Taylor & Francis
Introduction Brain metastases are one of the leading causes of death from non-small-cell
lung cancer (NSCLC). The use of epidermal growth factor receptor (EGFR) tyrosine kinase …
lung cancer (NSCLC). The use of epidermal growth factor receptor (EGFR) tyrosine kinase …
[HTML][HTML] Current progress and outcomes of clinical trials on using epidermal growth factor receptor-tyrosine kinase inhibitor therapy in non-small cell lung cancer …
LL Kong, LL Wang, LG Xing, JM Yu - Chronic Diseases and Translational …, 2017 - Elsevier
Non-small cell lung cancer (NSCLC) continues to be one of the major causes of cancer-
related deaths worldwide, and brain metastases are the major cause of death in NSCLC …
related deaths worldwide, and brain metastases are the major cause of death in NSCLC …
[HTML][HTML] Efficacy and safety of therapies for EGFR-mutant non-small cell lung cancer with brain metastasis: an evidence-based Bayesian network pooled study of …
B Zhao, Y Wang, Y Wang, W Chen, L Zhou… - Aging (Albany …, 2020 - ncbi.nlm.nih.gov
Preferable treatments for epidermal growth factor receptor (EGFR)-mutant non-small cell
lung cancer (NSCLC) with brain metastasis are elusive. The study intended to estimate the …
lung cancer (NSCLC) with brain metastasis are elusive. The study intended to estimate the …
Real‐world utilization of EGFR TKIs and prognostic factors for survival in EGFR‐mutated non‐small cell lung cancer patients with brain metastases
X Yu, J Sheng, G Pan, Y Fan - International Journal of Cancer, 2021 - Wiley Online Library
Brain metastases (BMs) cause morbidity and mortality in patients with non‐small cell lung
cancer (NSCLC). The optimal management of epidermal growth factor receptor (EGFR) …
cancer (NSCLC). The optimal management of epidermal growth factor receptor (EGFR) …
The optimal therapy strategy for epidermal growth factor receptor‐mutated non‐small cell lung cancer patients with brain metastasis: A real‐world study from Taiwan
Background The treatment options for epidermal growth factor receptor (EGFR)‐mutated
non‐small cell lung cancer (NSCLC) with brain metastases (BMs) include EGFR‐tyrosine …
non‐small cell lung cancer (NSCLC) with brain metastases (BMs) include EGFR‐tyrosine …
[HTML][HTML] Real-world data on prognostic factors for overall survival in EGFR-mutant non-small-cell lung cancer patients with brain metastases
X Yu, Y Fan - Journal of Cancer, 2019 - ncbi.nlm.nih.gov
Background: With the wide application of epidermal growth factor receptor-tyrosine kinase
inhibitors (EGFR-TKIs), the survival of EGFR-mutant non-small-cell lung cancer (NSCLC) …
inhibitors (EGFR-TKIs), the survival of EGFR-mutant non-small-cell lung cancer (NSCLC) …
Multidisciplinary expert opinion on the treatment consensus for patients with EGFR mutated NSCLC with brain metastases
S Ponce, J Bruna, O Juan, R López, A Navarro… - Critical reviews in …, 2019 - Elsevier
The presence of an epidermal growth factor receptor (EGFR) mutation is associated with
higher incidence of brain metastases in patients with non-small cell lung cancer (NSCLC); …
higher incidence of brain metastases in patients with non-small cell lung cancer (NSCLC); …
[HTML][HTML] The different overall survival between single-agent EGFR-TKI treatment and with bevacizumab in non-small cell lung cancer patients with brain metastasis
TH Chiu, PH Tung, CH Huang, JS Ju, ACC Huang… - Scientific Reports, 2022 - nature.com
Abstract Comparison of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-
TKI) monotherapy or with bevacizumab in real-world non-small cell lung cancer (NSCLC) …
TKI) monotherapy or with bevacizumab in real-world non-small cell lung cancer (NSCLC) …